Proliferation (FLT)

Ongoing clinical trials and approved products targeting Proliferation (FLT), in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

0ongoing therapy trials

6ongoing imaging trials

0approved products

Target note

Full name: Cell proliferation (thymidine kinase 1)
Nature: FLT is phosphorylated by thymidine kinase 1, active in S phase.
Normal expression: Bone marrow, liver.
Value: A proliferation marker more specific than FDG, for early response assessment.
Approaches: [18F]FLT.
Indications explored: Lymphomas, gliomas, breast and lung cancers (research).
Points of caution: Bone marrow and liver cannot be assessed.

Ongoing imaging trials · 6Open in the radar →

Trial	Phase	Status	Sponsor	Countries
[18F]FLTNCT02392429 · Leukemia / transplant conditioning	Phase 2	Active, not recruiting	National Cancer Institute (NCI)	1
REALIZE · [18F]FLTNCT03633955 · Lymphoma	Phase 1	Recruiting	University of Oklahoma	1
[18F]FLTNCT03422731 · Leukemia / transplant conditioning	Phase 1	Active, not recruiting	City of Hope Medical Center	1
REVEAL · [18F]FLTNCT03541889 · Leukemia / transplant conditioning	Phase 1	Recruiting	University of Oklahoma	1
[18F]FLTNCT02608216 · Breast	Phase 1	Active, not recruiting	University of Pennsylvania	1
[18F]FLTNCT00935090 · Brain (glioma, medulloblastoma…)	No phase	Active, not recruiting	Barbara Ann Karmanos Cancer Institute	1

Cite this page

Proliferation (FLT). Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/proliferation-flt/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.